OR WAIT null SECS
© 2021 MJH Life Sciences and Rheumatology Network. All rights reserved.
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
November 26, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 26, 2021.
November 25, 2021
Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.
November 24, 2021
Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases and Janssen’s role in scientific innovation that allows patients to live their lives unburdened by disease.
November 23, 2021
Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.
Janus kinase (JAK) inhibitors are the newest class of drugs used to treat rheumatoid arthritis. How much do you know about these drugs? Test your knowledge with this quiz.
November 22, 2021
Courtney Wells, PhD, MPH, MSW, discusses the impact of the pandemic on the quality of life of patients with rheumatic conditions, with an emphasis on perceived risk and decision making.
Robert F Spiera, MD, explains background mycophenolate treatment and its associated improved outcomes in patients with systemic sclerosis receiving lenabasum.
November 19, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 19, 2021.
November 18, 2021
Kelly Gavigan, MPH, discusses the changes in patient-reported outcome scores during the COVID-19 pandemic.
Eric Morand, MD, discusses “Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials.”